SELB - Earnings call transcript Q2 2021 | Cartesian Therapeutics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning, everyone, and welcome to the Selecta Biosciences Second Quarter 2021 Financial Results and Corporate Update Conference Call. Currently, all participants are in a listen-only mode. This call is being webcast live on the Investors & Media section of Selecta's website at www.selectabio.com, and is being recorded.

For opening remarks, I would like to introduce, Kristen Baldwin, Chief People Officer of Selecta. Please go ahead.

Kristen Baldwin

morning. good and you, Thank Welcome to update results corporate XXXX second call. quarter conference financial and our The our website, release & press supporting Media the available section Investors on of Selecta’s www.selectabio.com. financial results is Form And the was today the with ended XX, XXXX filed XX-Q SEC. quarterly which June on report

me Carsten Officer. President Brunn, Joining and Peter Officer; Scientific Executive today Kishimoto, Medical Chief Chief are Traber, Officer; our Chief and Takashi

prospects. statements Commission, with and the regulatory partnerships, Report including and we our to plans, will made described Exchange progress our and safety, Quarterly be These without XX-Q. statements limitation, call, forward-looking including various potential, are risks and statements today's Form that product During efficacy, Securities our certain filings most and clinical of subject projections the in candidates, the about recent are making financial on expectations, future

to You to on reliance disclaims of August place turn XX, are XXXX, only over now the if like I these to would Brunn. forward-looking obligation such to to Selecta as cautioned which speak management's views today, update call undue and change. Carsten statements, even not statements, any

Carsten Brunn

to next Kristen. therapies enzyme us mitigating through key gene milestones. achieved that walk advanced milestones of Selecta appreciate Good morning. therapies, commitment our us quarter, autoimmune our that, immune a several fields. ImmTOR and tolerance pipeline we joining immune To unwanted validated continues it's generation platform leading of antigen-specific in you, upcoming some the across last And take worth diseases. tolerogenic our through the to steadfast clinically updates I’ll and With you development start, responses emphasizing in Thank today. I selectively therapies. position

Sobi was of chronic refractory enzyme points which SEL-XXX, is our pegadricase, co-administered gout. for a our with of on licensed key therapy treatment uricase proprietary First, comprised the programs. ImmTOR few to

and one per and X X or top-line trials, of IgA in cause development trial SEL-XXX data of X.X environmental milligrams the third double accumulation expected with schedule As leverage kilogram X.XX pegadricase an clinical the the both our kicked placebo. aims at and on that for evaluated per complexes in two We success XX a nephropathy SEL-XXX. controlled abnormal is blind the to will disease ImmTOR kidney XX Each XXX placebo trials a kidney at in consists to IgA and of quarter immune Genetic from off milligrams in second kidneys dose progressing which X of two Phase disease. and In in is enroll can doses SEL-XXX XXXX, DISSOLVE Enrollment that indication antibody or of immunoglobulin patients to program the reminder, program the per of kidneys. DISSOLVE kilogram, be result called milligrams each of factors dose second-half on X.XX leads accumulates IgA AX and kilogram. and occurs is enzyme IgA when its the intend nephropathy, a of of in XXXX.

into the we overcome development, to potential we disease XXXX. our in to Although, novel treat root manufacturing push securing IND delay ImmTOR qualified X the has to believe associated IgA combines no which limitations there and a IgA our with are to the expect protease work, anticipated therapies, productive of Due development. with cause process CDMO protease approach approved previous and filing

chains ID successfully have challenges, has and resulted and Although, CDMO, currently secured underway. we the in recent impacted COVID-XX studies a are supply and enabling surge

in later year. the provide on our progress updates We will

vector the the dose formation trial volunteers of in and to no to SEL-XXX, mitigate capsids dose EMC-XXX AAVX escalation in aims antibodies The trial and our quarter in to gene Phase conducted empty of Now capsid being collaboration in DNA XXXX therapy the ImmTOR. determine initiated is of AAVX the combined first-in-human with to turning first gene with containing we healthy of or programs, ImmTOR used AskBio, the X therapies. regimen

made We’re pleased and on progress with the remain to-date track.

our in We the expect we that disclosed has or fourth been rare of MMA, acidemia cannot of ongoing completed, we AAVX MMA-XXX first to a manufacturing EMC The report was to and new undergoing previously XXXX. exclusive is for on third-party quarter release a rights therapy break wholly-owned And testing. down and also AAV quarter therapy treatment Building MMA-XXX, body in manufacturing methylmalonic disease final capsids fats. are metabolic by data pleased in which study proteins top-line certain XXXX, issue gene lot the and currently strengthened vector the of resolved. our regaining of gene portfolio the

expression We expect Therapy Methods for safety vector publication is mouse and & after in which of AAV a further commence MMA. evaluate program, Clinical our of an gene pipeline, ImmTOR relevant combination quarter of gene MMA SEL-XXX, biomarkers of validates in The disease, lead development of clinical and to is Further, which publication journal expected to file our The during the the SEL-XXX. plus and ImmTOR repeat will SEL-XXX of the X/X use especially an the MMA-XXX recent initial tolerability. dosing enhances therapy demonstrated in model the of utilizing ImmTOR in our Molecular transient antibodies, XXXX candidate Phase therapy XXXX. observation of both third the that IND our in for Development

to gene disorder in OTC cycle. is gene, mutations proprietary function wholly-owned therapy deficiency OTC ornithine OTC genetic is second product or candidate caused which SEL-XXX excellent the an critical proper deficiency. the is urea Our treat transcarbamylase by genetic for being of developed

in application file to or XXXX. PIP Looking submitted European plan in an committee investigation trial pediatric for XXXX. the clinical and/or to Agency February Medicines SEL-XXX pediatric ahead, expect the We we or IND a CTA

we Therapeutics Sarepta. forward criteria validates dystrophy in as constraints seeing dystrophies this preclinical disorders Overall, closer AAV-driven building platform. This the we this potential we received we with and in up gene meeting dosing Before We ImmTOR repeat immunogenicity milestone dose. recently muscular muscular to and more as and we the and wrap gene or expression license overcome subtypes. to step on of Duchenne look the research in of move and certain successfully progress preclinical limitations X DMD at after addressing as payment combination antibodies, neuromuscular enable to work study further conduct one preventing Sarepta of by durable therapy, strive first million of LGMD on under including option robust agreement continues a momentum or limb-girdle ImmTOR’s to for formation we're excellent neutralizing therapy, transgene the the looking

our autoimmune moving to Now, program. on

damage of antigen, progressive treatment in to PBC shows significant induction data to in chronic publication autoimmune application that liver-specific Frontiers liver, inflammation, of PBC, major well of supports it's that published protective populations, demonstrated diseases, recently a the tolerogenic disorder need for immune tolerogenic autoimmune including biliary hepatic platform. autoimmune acute phenotype ImmTOR The and scarring further ImmTOR the was of cholangitis a ImmTOR Immunology, Selecta’s in liver well-defined an in ducts. small leads Our model environment the hepatitis. primary presenting unmet all of in bile development of platform cell enhances antigen medical suited and the or target the tolerance and a has our

enabling an the PBC IND through IND advancing XXXX. and of in to second-half studies, and is program autoimmune we Our expect find

XXXX, Phase for of XX, as We of agreement the the through revenue of DISSOLVE million $XXX.X for which million supply in $XX.X same from We XXXX. XX, June same costs liquidity shipment our for months for was Revenue period which I'll remain to March had was license well-capitalized. results be compared million compares to our of as to quarter XX, as million was the the Now, second began the run operating XXXX, recognized XXXX, XX, in period XXXX. quarter recognition six $XX.X operating financial XXXX. June $XXX.X to requirements with the June cash ended in $XX.X July believe for of the clinical compared Revenue no XXXX. our into recognized second incurred and for liquidity the Net clinical will liquidity million under the XXXX. activities meet sufficient of quarter program. Sobi, We X in third resulting used ended reimbursement XXXX

for from development second $X.X XXXX. which Additionally, and term were grant. for agreement the $XX.X Sarepta audit Foundation contractual during than $XX.X shipments less the of the second the million, resulting of in expenses compares Skolkovo we $X.X for Research and period million million exploration under the with quarter, the XXXX under million with license same recognized quarter the

discovery and During primarily reduced patent decrease the and preclinical for and compares in million, expenses same for General, the expenses by stock the for salaries, the a offset million offset professional were for XXXX was collaboration second quarter expenses. programs an there XXXX, fees, salaries costs. with costs which increased period ended June in by $X.X of decrease compensation result was quarter consulting AskBio consulting, and of in expenses XXXX. expenses, The administrative the increase $X.X XX, incurred

For the the XXXX. compared $X.X we period or income loss net loss basic second or of report a quarter net income share $XX.X same $X.XX, per $X.XX XXXX, basic to of million million share per net net of of for in

call, Before there's share. to concluding today's few a corporate updates

Dr. for human Selecta’s He Directors. most private was muscular Silva lifetime AAV by Board experience currently AFYX consulting. excited Officer in Chief Gene Dr. manufacturing, industry Disease has the the therapies recipient de was we Scientific de and brings he University a Achievement Dr. decades. XX-years contributions biotechnology of capital oversaw over Dr. into has President, Chief experience, a leader Operating biopharmaceutical giant gene healthcare and Poseida company, Therapy North inflection Executive of Dr. Together, Duchenne Outstanding AskBio. Chief awarded currently the therapy has Officer focused of management & is mucosal biotechnology Co-Founder in Silva clinical for Dr. relevantly is a the Center activities. Dr. be dystrophy, Jude leadership in a development, served Silva clinical failure. We're we're As manufacturing, activities. President, gene of Nishan we is operations, and Therapeutics, development, Samulski therapy-focused in Previously Silva’s Director development, as and regulatory to of development as therapy venture will clinic. finance, extensive de Society Silva gene for welcome company been gene Therapy axonal biopharmaceutical to and where and invaluable advisor. as achievements He and and the of Award Director also diseases. Officer and of and American Carolina into addressing a for cell to neuropathy, a continue regulatory, heart Therapeutics, professor business addition de trials hemophilia, advanced on pioneer Director de advance viral patent He the needs of unmet Pompe Cell point enter pleased two He venture-backed vector, Samulski and of gene first of therapy. the of in Samulski critical pharmacology first special Gene over

conclude about investigators, we As mentioned team who've company, our growth we're remain continued their the I'd our been questions. in happy reiterating many Operator? at our to extremely our earlier, including families, gratitude Selecta. and confident With and the to people to take along way, like our by the that, supportive platform. excited patients great our of and we're

Operator

[Operator Ladies session. Our Kluska Cantor question-and-answer with and your Please go at gentlemen, from from Kristen comes question this Fitzgerald. time question. first today begin ahead the we'll Instructions]

Kristen Kluska

and Hi, for good questions. my thanks morning, taking

rank importance recent rank treatment, where to them of durability and a gene dose hemophilia frequency to most patients therapy there actually greatest important B publication a as patient. were was hemophilia asking which found for So, aspects the surveyed the

this you've that but you've evaluated believe publication know and I therapy your the one molecular preclinical for therapy. data of a year, published ImmTOR So lot longest of recent I presented gene studies in was

could re-dosing aspects. the other on to durability discuss trends you through we'd ask potential generally including please implications the that you ImmTOR observed and durability, could like So speaking, you've think if on key here, have and

Carsten Brunn

for question, Kristen. the Thanks

on a You're data frequency issue, bit a let study. we're is detail pleased in physicians And durability Kei patients. with and for Kei? findings more the we little dose have comment right, both that key I’ll the and to-date.

Takashi Kishimoto

Good morning. Yes.

only we're activity and not that after actually think transgene I expression re-dose, seeing two study One, first significant of highlighted dose. we can enhancement but the things. So

we dose. been haemophilia So, of patients. ImmTOR far of that gene as adding and say think has durability, adult is therapies, large, benefit second both And to you by there's first concern. and so restricted at Obviously, actually to a the

of question more I pressing, So the think, for indications. pediatric becomes durability even

Kristen Kluska

which data And know study then the assessment you Thanks. the including will initial now, you're Okay. also ask you then, will guiding antibodies? focus to this the neutralizing with do but as I trial first-in-human think next And do what question the safety that and year, as to think you conducting items we in XXXX, of AAVX currently the could empty helped study the be think wanted answered trial? I you're in capsids be later next data on year, launch year key MMA some to important biomarker see well? And with

Carsten Brunn

great a question. that's Yeah,

So looking the when in from able AAVX prevent as capsids with levels at will non-human antibody. able and the formation in empty primarily the expect ImmTOR. look we would we to what primate we're guided, terms capsids with of co-administered seen results prevent year. to quarter we of we at we've of the have fourth a what And XX-day are antibodies, what data, we And, that are of data, with we really this is, empty study

really us. of at two study the readout important doses. very that to is in a looking it's ImmTOR, find dose essence, goal But escalation the dose primary right we’re So for

terms know, pleased Kristen, so to the we're we trial, able detail, year. in of as we're haven't IND file third in but quarter this the MMA guided In of that you the

bit of previous guidance a given. ahead So that the we've little

XXXX. the antibodies, ability also will and IND it's show views think but primarily the look least off be FDA We is possibility guidance and that we're say safety it's that, focusing, at, after formation there we'll I to the in But going to at something will fair obviously detailed more to be we're the able biomarker some give file. Obviously, on cohort sure. to biomarkers first for study prevent neutralizing the

Kristen Kluska

Great. you. Thank

Operator

Our comes William Please question. from with from Prasad question go your Blair. next Raju ahead

Raju Prasad

regards the XXX at testing that study? taking doses us you're you look next little different give of how disease-specific running a you're for if could going question. have in question. year? that the kind of Maybe And you of in some on color ImmTOR just Thanks to the are data I bit that And the another trials to of

Carsten Brunn

a Raju. Yeah, question, great that's

per we're looking doses in in chronic empty dose kilogram, you as the milligrams milligrams of So gout. Both X.XX that we into X.XX capsids doses the in kilograms. looking clinic in-humans, Phase forward per for doses, terms We're study. refractory at know, been the X.X X two take in at have and and currently

We yet submitted the haven't guided MMA, feedback. once the IND dose we application use to we have we're and going will in FDA the to on receive do that

one dosing in we in require non-human just we're doses, primate prevent times, the up the see I additional to study, Raj, to think whereas this, three Phase one, we XX you gene maybe antibodies. of look comment less X, around neutralizing gout we doses in therapy, at inflammation likely need

don't think to possibility given dose to I higher therapy, a up XX to in doses. use actually there's So we plan a gene give

the So, unless guidance filed but consideration, there's give further after we'll we've IND.

Raju Prasad

MMA and the and anything more Is population with about indications thinking OTC, regarding antigen you're disease the being population, the primarily pediatric or dosing? prevalent

Carsten Brunn

don't we disclose details high use. think pediatric But general some a I level. understanding, just Yeah, an have I’ll ready question. Peter? tropomyosin bit yet. we're let that's talk Peter important Actually, little to

Peter Traber

some including information a of renal on [ph] in of cancer number transplant, patients, Sure. the is labomyosin There treatments. use pediatric

of a bit know children pharmacokinetics comparison between higher do we pediatrics. while in our adults, the believe to in and and from so, pediatrics actually approach dosed levels the And rate, will have we a labomyosin we adults. clearances lower of comparison be where standpoint haven't ImmTOR tolerable and safe therefore, And of that children, about clearance in

our margin. So, we've we course, labomyosin then bit a the in we doses with used will And of levels. able be of dosing to with with think we'll same guide continued adults dose a safety that

Raju Prasad

then quick just follow up. And one Great. maybe

in on ASTCT, dosing the had preexisting antibodies. of presence the maternal at preclinical a presentation you think I

thinking using still ImmTOR antibodies? bonafide patients derived in maternal versus antibodies you're kind of with about So preexisting

Carsten Brunn

well. Yeah, that's a as good question Raj,

So, currently think don't ImmTOR humans, we that antibodies. in preexisting addresses

such give is Obviously, thinking maybe other We Kei think let current we the would gene in that preexisting of of criteria outside potential IgA treatment -- the that in for for with that to excluding But or to I’ll would that that comment use we as gave. address adults. antibodies. other protease, there the patients population So context lower example. kids is are as therapies, unmet presentation and ImmTOR with approaches we bit you an terms need, a same

Takashi Kishimoto

we some said, ImmTOR antibodies. Carsten terms antibody so patients, think so in as negative, are give that But But in have low we on I levels when naive patients levels. seen Yeah, words, with enabling it's see animals. for robust of we gene very data that preexisting AAV effect in re-dosing limited those that with patients for therapy other ImmTOR of think of high I

Raju Prasad

for you the question. Thank

Operator

Our next your ahead question. Canaccord. question comes with go from Newman from John Please

John Newman

my Thanks taking question. for

So a empty to coming capsids questions couple asked along question data later ask of up this there's is something already been vein. wanted different a regarding I year. the

example, year, assume look ImmTOR some Thanks. later Not question that dose be are the out is, that that I much in terms effectively And seeing we you ImmTOR commenting it sort a up should And but companies Just in landscape? do you of the ImmTOR to reasonable know curious the MMA competition formation remain neutralizing at study, So at you're re-dose that assume dosing the any constant are you're doses? regimen would aware not moment? to antibody of you to dosing, see area? that the able this prevent as of multi of then, able would would the ImmTOR? at on many next wouldn't, really step companies to for in dosing what of

Carsten Brunn

enable And the formation issue, I antibodies. has to knowledge, in mice, our times John. to Yeah, have the we dosed quite prevent re-dosing, and so it position, unique demonstrated in we're formation believe I actually. reduce think we're terms this Thanks, a think company of three neutralizing To four of ability to that questions. up neutralizing to competition, we only of do Great address antibodies or times. Yeah. comes the when actually

So chronic done knowledge refractory ImmTOR up dosed gout, that broad have to and this. clinical in very patients close what only our like six other with ImmTOR now, with XXX that experience to company has we're we think, to XXX, And obviously, the we have I indications, months.

But formation, believe enzyme one unique prevent be position. data to address three quarter. a question ability MMA, you're the find which actually, then in right. data, there's obviously, use antibodies. the itself. In which doses and in on of of non-human But the we the we protease think primate fourth preexisting actual on to we're might approach, is prevent IgA And your formation to the have quite an immunogenic we'll it complimentary ImmTOR regards antibodies. to like interesting, terms I is quite in definitely, are required the to looks Based of the

But We Phase the changed and the guide to the not earlier, yet to used after we not as position IND We've with have throughout. on same we detail X/X this always filed do mentioned We'll dose. the study. dose we’re FDA. in dose, the that

John Newman

Okay, great. Thank you.

Operator

Yang next Difei Mizuho from your with question. Please go ahead from comes Securities. Our question

Dan Clark

Hi, good morning. This for is Dan Clark Difei. on

actually non-viral I therapy and a of Just we'd the And two AAV curious be as have us. thoughts To gene on from delivery methods John's your get ImmTOR. off versus of Thanks. start, follow-up question, well. piggybacking to combination

Carsten Brunn

X,XXX and that's not obviously, and just now also right away. that, but They say Yeah, are approaches. in grout fairly with on will over non-viral clinical registered lot great the those terms evidence. AAV of exact capsids, excitement it's of me question. and in think fair go that's there's I trial it's don't clinical a I quote number, therapy But noise to -- And trials gene think of a early

think moment. very approaches I think, I but interesting, the at are they're our early none stage of

Dan Clark

have data liver? Great. the Thank transgene on on you. this of expression do And you. you going then is Sarepta the targets And sort of ImmTOR improving collaboration? what's and any in Thank than other part

Carsten Brunn

study than to milestone successfully liver a we Kei neuromuscular in previously done than have up disease about. all tear It we've knowledge, it obviously used, for obviously the was Sarepta we preclinical as not let as which but I’m great to other very far my meeting received is a diseases. the in well, but can’t higher can’t as thrilled a comment I’ll we you data we Unfortunately, a dose work sure the add? that's comment, in also that comment model that unfortunately. anything base Kei on million Yeah, we're else X question. and have

Takashi Kishimoto

I really add Yeah, have to don't anything to that.

Carsten Brunn

Thank you.

Dan Clark

Thank you.

Operator

from Yun comes question. go Please Zhong next with Our BTIG. from your question ahead

Yun Zhong

Okay. Thanks much for the question. very taking

And be I the looking as AAVX question at different So, the you different for probably are of confirm just that have will or effect wonder different to study. capsids a capsids, given different on And wanted single on well, to ImmTOR the capsids I doses? will empty just whether of doses the indications that, for dose? companies try of dose AAVX dependent

Carsten Brunn

a Yeah, thanks for question. the That's question, good Yun.

a is single important using empty volunteer this dose in mind, we're So it's of keep of two capsids. AAVX E-XX study. a to Obviously, healthy

higher dose. So feel to with and the a kilogram it kilogram. didn't testing two doses appropriate milligrams ImmTOR, milligrams of X.X per we per we're go And X.XX was

idea have those healthy So higher was data of it with showed good antibodies in some higher dose doses for We of to a this AAV and setting in go good think we didn't with reasons. a just safety volunteers. control non-human

Yun Zhong

you. Thank Great. Okay.

Operator

Company. question ahead Gil Needham Our your with Please & comes from next go question. from Blum

Gil Blum

Hi, our good for and morning, taking question. thanks

AAV? Do meeting as guys you. you at all? aware, come will first Thank you guys there an are And there's well all, up as immunosuppressant, potential safety a probably think advisory of secondly, safety ImmTOR AAV. to administration general is So of upcoming around for improve committee for considering it the of that as an re-dosing topic

Carsten Brunn

comment around safety. we're data let Peter some AdCom, But, the Yeah, obviously so of. which aware have Kei we or on I’ll encouraging

the hyper in ImmTOR that in not MMA humans, We have only trends is observed protective has elevated Obviously, properties. animal studies. demonstrated

highly we that So compelling obviously, I we're not have that data is pretty, able hepatoprotective. around But to specifically ImmTOR shows conduct think, that. experiments

safety sparing as which the we've dose AdCom? in approach, dose, benefit with, dose anything some after higher the a potentially on to lower positive Peter, of AAV. events also safety, also very doses first to add which high shown are or record the dose safety is have reported having death think most first begin you of I worth the as efficacy that a use terms of of means effect, the first other The

Peter Traber

No, I we about we're have except this. gene talking don't a of its the ImmTOR ability And anything had add, input that potentially quite to are that interested and to Kei has fortunate in in therapy. into FDA, lot change the game

And interested when comment, of that being it. the it we with so antigens the advantages we tolerized time. specifically same they're to talked mention well-aware don't immunosuppress just one Selecta’s globally ImmTOR, that, immune is and thing give that's immunosuppressive, the made of actually, would in at really we our that I technology very one you ImmTOR an Gil you about

humans. antigens, So have a contraindicated would have approach in that rather approach. about relatively in and are able using as MMA, who Carsten a the Steroids number on we're And immunosuppressants such I may that be that to get hope of therapy. hope because indications getting they're that's to in tolerance AAV be point we steroids board, side to ImmTOR to targeted important based AAV say across to in we've we the of of able kinds immunogenicity reducing all because a whereas very animal and studies replicate lot fact in the people effects we liver seen also said that OTCD. spare what

the addition be reducing could hepatotoxicity. steroids so, also useful effect in to sparing And

Takashi Kishimoto

the patients. FDA also elevation animals AAV. what we've And humans because seen seen liver. in have in transaminase is liver mentioned, animal elevation. observed inhibition AAV-specific associated inflammation studies, might of that, models add can't T-cells CDA CDA been in have unfortunately, other T-cell in liver this study previously, that the of of -- in it's activation of have I concerns Yeah, in to And and liver then mitigate one animal the is And inflammation finally, seen CDA-specific and with of we ImmTOR that's we Carsten expressing liver specifically that does only been often in the shown as the But that liver inflammation. appearance response without cells the we enzyme

Operator

ahead comes question from your Our go question. next from Please Wainwright. with Ram H.C. Selvaraju

Boobalan Pachaiyappan

Hi, in thanks this is Selvaraju. for my Boobalan taking And Ram question. for dialing

where So very so particular obviously, helpful to you? are Professor will Samulski, you his programs there be expertise hired very,

Carsten Brunn

all have the this great you Yeah, work pleased we the with, as We're Samulski. as return as gene fully Dr. therapy very across know, AskBio support with part obviously, this is able our focus to owned. now agreement. program have Selecta on And a And that clearly of familiar question. us is he programs that He'll right that we we're program. MMA,

other brings expertise, he with So and clinic. programs used initial as a the just lot can really of OTC strengthen preclinical also be working understanding focus. he's the indication But ImmTOR well, the deficiency and to that's on in us our of how

Boobalan Pachaiyappan

me. more And Great. one from

program narsoplimab? nephropathy like against a stack IgA your does drug how up So

Carsten Brunn

approach learnings of serum basically where a think deposits. patients quite really in the we're step of on acid nephropathy. gout trying so and what of kind program Yeah, to And SEL-XXX, in building about I do here, we have just we're unique we our refractory uric chronic IgA back,

root quite of using to develop Here, addresses IgA protease, immunogenic patients of is X IgA And underlying the the IgA an kind we're immune cause X also an the moment at we're which to [ph] therapeutic complex actual disease, complex of origins the of approach deposit. the our only deposits. that understanding,

think So differentiated perspective. quite from we that it's

Boobalan Pachaiyappan

it That's Thank you. from me. Okay.

Operator

with from follow-up. go a Canaccord. ahead from Please John question our And follow-up is Newman your next

John Newman

there. Hi,

follow-up therapy. a and re-dosing gene regarding Just

an So about and re-dosing just we're are gene that I of the about the I guess, for is not some therapy, are faced, the think third question your what But issues Thanks. dose? other some for able or that us work wondered when I the you've clinical trials? to in second team. field we the if issues being remind that you issue, could give mainly in seen think in example, thinking are a of

Carsten Brunn

first dose Yeah, challenge there's here, couple often a X in that's of to the a the I is The right. study. -- John. applications Phase great find question, a key mean, right

If able you you're second low, a not dose dose. give to too

be ImmTOR. a could that application potential for So

up You’re able low you your were in titrate if to too dose. first

very studied indications high ducts magnitude where is well. the Another doses at muscle have yet, in you concerns really doses, where least give earlier. I data discussed be that approach potentially, well, bile a this potential avoid potentially might of think approach that's data, we in and theoretical to to approach very able of And you give the were quite animal compelling interesting lower some we but as disorders, that the EXX, haven't this sparing pretty especially we're in multiple as like your dose safety

the potential think another give of But now dose key driver being is -- second terms right that's the limitation able limitation not to right So in biggest clearly really of need and now. application. the I a

John Newman

you. Thank Great.

Operator

And for I ladies to that conclude to turn will portion remarks. back question-and-answer now call. the conference the closing we call gentlemen, Selecta’s over Brunn with of CEO, today's and would Carsten like Carsten?

Carsten Brunn

Thank thank today's And and you. and call. you, joined healthy. concludes Stay operator Thank you, this safe us morning. who this everyone

Operator

conclude does We that call. conference attending. you today's do thank gentlemen, and Ladies for

your disconnect lines. now may You

Cartesian Therapeutics (RNAC) 12 Aug 212021 Q2 Earnings call transcript